Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase NA 3Phase 1 3Phase 1/2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Cancer Metastatic 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 182Docetaxel 166Gemcitabine 165Oxaliplatin 162Carboplatin 160Paclitaxel 152Leucovorin 122Drug Therapy 118Dexamethasone 118Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 56Neoadjuvant Therapy 53Lenalidomide 52Letrozole 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER × dalpiciclib × Clear all
NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 3 Active not recruiting
307 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡